12:00 AM
 | 
Jun 11, 2012
 |  BioCentury  |  Emerging Company Profile

Armetheon: Stopping the bleeding

Armetheon refocusing anticoagulant tecarfarin on underserved population

Former ARYx Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin three years after the ARYx anticoagulant failed a Phase II/III trial to prevent blood clots. This time around the focus is on chronic use in the narrower population of atrial fibrillation patients with renal insufficiency, a group whose needs aren't met by available therapies.

Tecarfarin (formerly ATI-5923) is a long-acting anticoagulant that inhibits vitamin K epoxide reductase (VKOR). Armetheon acquired the asset from now-defunct ARYx this year. Investors lost confidence in ARYx after FDA delayed responding to a request for an SPA for Phase III testing of naronapride (ATI-7505), a gastrointestinal disorder compound, according to Milner.

Compared to warfarin, Armetheon expects tecarfarin will need less frequent monitoring and produce fewer drug-drug interactions because tecarfarin is metabolized by tissue esterases, not the cytochrome P450 metabolic pathway used by many drugs.

The company also believes tecarfarin could address needs...

Read the full 777 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >